IDE and Alzheimer disease: In a double-transgenic AD mouse experiment, Yun et al. (2022) found that ginsenoside F1 exerts its beneficial effects by increasing insulin-degrading enzyme (IDE) and neprilysin (NEP) expression, providing scientific evidence regarding the applicability of Aβ treatment in AD patients.